ID: ALA2441433

Max Phase: Preclinical

Molecular Formula: C21H23N7O3

Molecular Weight: 421.46

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(Cc1ccc(-n2cnnn2)cc1)N1CCN(CCc2ccc([N+](=O)[O-])cc2)CC1

Standard InChI:  InChI=1S/C21H23N7O3/c29-21(15-18-3-5-19(6-4-18)27-16-22-23-24-27)26-13-11-25(12-14-26)10-9-17-1-7-20(8-2-17)28(30)31/h1-8,16H,9-15H2

Standard InChI Key:  VWVVYFJIUBMXBZ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 421.46

Molecular Weight (Monoisotopic): 421.1862

AlogP: 1.50

#Rotatable Bonds: 7

Polar Surface Area: 110.29

Molecular Species: NEUTRAL

HBA: 8

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 6.84

CX LogP: 2.09

CX LogD: 1.98

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.42

Np Likeness Score: -2.22

References

1. Tang H, de Jesus RK, Walsh SP, Zhu Y, Yan Y, Priest BT, Swensen AM, Alonso-Galicia M, Felix JP, Brochu RM, Bailey T, Thomas-Fowlkes B, Zhou X, Pai LY, Hampton C, Hernandez M, Owens K, Roy S, Kaczorowski GJ, Yang L, Garcia ML, Pasternak A..  (2013)  Discovery of a novel sub-class of ROMK channel inhibitors typified by 5-(2-(4-(2-(4-(1H-Tetrazol-1-yl)phenyl)acetyl)piperazin-1-yl)ethyl)isobenzofuran-1(3H)-one.,  23  (21): [PMID:24075732] [10.1016/j.bmcl.2013.08.104]

Source

Source(1):

• Scientific Literature